Nuvalent (NUVL) Non Operating Income (2020 - 2026)
Nuvalent (NUVL) reported Non Operating Income of $10.3 million for Q1 2026, down 0.88% on a YoY basis from $10.4 million in Q1 2025, and up 276.27% quarter-over-quarter from -$5.8 million in Q4 2025.
Nuvalent (NUVL) Non Operating Income (2020 - 2026) Analysis & Trends
Nuvalent has reported Non Operating Income for 7 years, with the latest figure at $10.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 0.88% year-over-year to $10.3 million; the trailing twelve-month figure through Mar 2026 stood at -$91000.0 (down 100.41% YoY), and the FY2024 full-year result was $20.4 million, down 12.45% from the prior year.
- Non Operating Income for Q1 2026 stood at $10.3 million, up from -$5.8 million in the prior quarter.
- The five-year high for Non Operating Income was $11.7 million in Q4 2024, with the low at -$9.6 million in Q3 2025.
- Historically, Non Operating Income has averaged $3.4 million across 5 years, with a median of $5.0 million in 2023.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 67100.0% — and 2024, when it plunged 255.2%.
- Nuvalent's Non Operating Income stood at $3.2 million in 2022, then jumped by 156.45% to $8.1 million in 2023, then jumped by 43.73% to $11.7 million in 2024, then slumped by 149.89% to -$5.8 million in 2025, then soared by 276.27% to $10.3 million in 2026.
- The last three Non Operating Income figures came in at $10.3 million (Q1 2026), -$5.8 million (Q4 2025), and -$9.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 9.35 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 10.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.30 Mn |
| Dec 31, 2025 | -5.84 Mn |
| Sep 30, 2025 | -9.61 Mn |
| Jun 30, 2025 | 5.06 Mn |
| Mar 31, 2025 | 10.39 Mn |
| Dec 31, 2024 | 11.71 Mn |
| Sep 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | 8.15 Mn |
| Mar 31, 2024 | 8.49 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | 5.02 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 672,000.00 |
| Jun 30, 2022 | 267,000.00 |
| Mar 31, 2022 | 139,000.00 |
| Dec 31, 2021 | -546,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 12,000.00 |